人民财讯9月7日电，君实生物(688180)9月7日晚间公告，近日，公司产品重组人源化抗IL-17A单克隆抗 体(代号：JS005)在治疗中重度斑块状银屑病的一项多中心、随机、双盲、平行、安慰剂对照的关键注 册性Ⅲ期临床研究中取得阳性结果，共同主要研究终点和关键次要终点均具有统计学显著性和临床意义 的改善。公司计划将于近期向监管部门递交该产品的上市许可申请。 ...

Core Viewpoint - Junshi Biosciences (688180.SH) announced positive results from a pivotal Phase III clinical trial for its product JS005, a humanized anti-IL-17A monoclonal antibody, in treating moderate to severe plaque psoriasis [1] Group 1 - The clinical study (JS005-005-III-PsO) was a multicenter, randomized, double-blind, parallel, placebo-controlled trial [1] - Both primary and key secondary endpoints showed statistically significant and clinically meaningful improvements [1] - The company plans to submit a marketing authorization application to regulatory authorities in the near future [1]

证券代码：688180 证券简称：君实生物 公告编号：临 2025-050 上海君实生物医药科技股份有限公司 自愿披露关于抗 IL-17A 单抗治疗中重度斑块状银屑 病的Ⅲ期临床研究达到主要研究终点的公告 JS005 是公司自主研发的特异性抗 IL-17A 单克隆抗体。IL（白细胞介素）-17A 是一种具有多效性的细胞因子，其分泌失调与自身免疫性疾病如银屑病、类风湿 关节炎、强直性脊柱炎等疾病的发生发展密切相关。JS005 通过与 IL-17A 高亲 和力结合并选择性地阻断 IL-17A 与其受体 IL-17RA/IL-17RC 的结合，从而阻断 下游信号通路的激活和炎性因子的释放，能有效地缓解自身免疫性疾病的症状。 截至本公告披露日，JS005 用于治疗中重度斑块状银屑病的Ⅲ期临床研究已达到 共同主要研究终点和关键次要终点，JS005 用于治疗活动性强直性脊柱炎的Ⅱ期 临床研究的所有参与者已完成主要终点访视，并进入延伸治疗期。 二、关于 JS005-005-Ⅲ-PsO 研究 银屑病是一种免疫介导的常见慢性、复发性、炎症性、系统性疾病。其患病 率在不同地区之间有较大差别，全球范围内银屑病总体患病率为 2.0% ...

Core Viewpoint - Junshi Biosciences announced positive results from the Phase III clinical study of its humanized anti-IL-17A monoclonal antibody JS005 for the treatment of moderate to severe plaque psoriasis [1] Group 1: Clinical Study Results - The study was led by Professor Zhang Jianzhong from Peking University People's Hospital and conducted across 60 research centers nationwide [1] - The primary objective was to achieve at least a 90% improvement in the Psoriasis Area and Severity Index (PASI 90) and a static Physician's Global Assessment (sPGA) score of 0 or 1 at week 12, comparing JS005 to a placebo [1] - Results indicated that JS005 significantly improved psoriasis lesions and severity compared to the placebo, with a higher proportion of participants achieving an sPGA score of 0 or 1 [1] Group 2: Safety and Regulatory Plans - The safety profile of JS005 was found to be good among participants with moderate to severe plaque psoriasis [1] - The company plans to submit a marketing authorization application for the product to regulatory authorities in the near future [1]

Core Viewpoint - The resignation of independent non-executive director Yang Yue and the subsequent nomination of Yang Jin as her replacement are aimed at maintaining the governance structure of Junshi Biosciences, ensuring compliance with legal requirements and the smooth operation of the board [1][3][5]. Group 1: Director Resignation - Yang Yue resigned from her position as an independent non-executive director and committee member due to other work commitments, effective immediately [1][2]. - Her resignation does not affect the board's minimum member count or its normal operations, and she will continue to fulfill her duties until a successor is elected [1][2]. Group 2: Appointment of New Independent Non-Executive Director - Yang Jin has been nominated as the candidate for the independent non-executive director position, pending approval at the upcoming shareholders' meeting [3][5]. - Yang Jin possesses the necessary experience and qualifications to fulfill the role, with no legal restrictions on his appointment [3][6]. Group 3: Adjustment of Board Committees - Following the resignation, the board has approved adjustments to the specialized committees, including the appointment of Yang Jin to the remuneration and assessment committee and Lu Kun to the nomination committee, effective upon shareholder approval [5][6]. Group 4: Upcoming Shareholders' Meeting - The first extraordinary shareholders' meeting of 2025 is scheduled for September 26, 2025, where the nomination of Yang Jin will be among the agenda items [7][8]. - The meeting will utilize both on-site and online voting methods, ensuring broad participation from shareholders [8][10].

Core Viewpoint - On September 5, 2023, Junshi Biosciences (君实生物-U) executed a block trade amounting to 47.66 million yuan, with a transaction volume of 1 million shares at a price of 47.66 yuan, reflecting a discount of 0.71% compared to the closing price of the day [1] Group 1: Trading Details - The block trade involved a total of 1 million shares, with a transaction value of 47.66 million yuan [1] - The transaction price was 47.66 yuan, which is 0.71% lower than the closing price of 48.00 yuan [1] - The buyer was from Founder Securities Co., Ltd., while the seller was from CITIC Securities Co., Ltd. [1] Group 2: Market Performance - On the same day, Junshi Biosciences closed at 48.00 yuan, marking a 7.38% increase, with a trading volume of 1.173 billion yuan and a turnover rate of 3.30% [1] - The net inflow of main funds for the day was 14.98 million yuan, while the stock saw a cumulative increase of 6.69% over the past five days [1] - The stock experienced a net outflow of funds totaling 5.82 million yuan over the last five days [1] Group 3: Margin Trading Data - The latest margin financing balance for Junshi Biosciences is 1.296 billion yuan, which has increased by 32.97 million yuan, representing a growth of 2.61% over the past five days [1]

Core Points - Junshi Biosciences announced the resignation of Ms. Yang Yue from the board of directors due to other work commitments [1] - Ms. Yang served as an independent non-executive director and was a member of the remuneration and assessment committee as well as the nomination committee [1] - Following her resignation, Ms. Yang will no longer hold any position within the company [1]

此乃要件 請即處理 閣下如對本通函任何方面或應採取的行動有任何疑問，應諮詢持牌證券交易商、銀行經理、律師、專業會 計師或其他專業顧問。 閣下如已售出或轉讓名下所有上海君實生物醫藥科技股份有限公司的股份，應立即將本通函連同隨附的代 表委任表格送交買主或承讓人，或經手買賣或轉讓的銀行、持牌證券交易商或其他代理商，以便轉交買主 或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本通函全部或任何部份內容而產生或因倚賴該等內容而引致的任 何損失承擔任何責任。 本通函僅供參考，並不構成收購、購買或認購本公司證券之邀請或要約。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 選舉獨立非執行董事 建議修訂部分內部管理制度 變更註冊資本、取消監事會、建議修訂公司章程及議事規則 建議採納2025年A股股票期權激勵計劃及 建議向一名董事兼主要股東授予A股股票期權 建議採納2025年A股股票期權激勵計劃實施考核管 ...

為上海君實生物醫藥科技股份有限公司（「本公司」） （附註2） SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 股A股╱H股 （附註3） 的註冊持有人， 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 於2025年9月26日（星期五）舉行之2025年第一次臨時股東大會之代表委任表格 本人╱吾等 （附註1） 地址為 （附註1） 茲委任大會主席 （附註4） 地址為 為本人╱吾等的委任代表，代表本人╱吾等出席本公司謹訂於2025年9月26日（星期五）下午二時四十分假座中華人民共和國上海 市浦東新區平家橋路100弄6號7幢15層舉行的2025年第一次臨時股東大會（「臨時股東大會」）或其任何續會，藉以考慮及酌情通過 召開臨時股東大會的通告中所載的決議案，並於會上代表本人╱吾等依照下列指示投票。倘無作出任何該等指示，則本人╱吾等 的委任代表可酌情投票及就或會於臨時股東大會及╱或其任何續會上正式提呈的任何其他事宜投票。 除另有指明者外，本代表委任表格所用詞彙與本公司日期為2025年9月5日的通函所界定者具有相同涵義。 | | 普通決議案 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 上海君實生物醫藥科技股份有限公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 臨時股東大會通告 茲通告上海君實生物醫藥科技股份有限公司（「本公司」）謹定於2025年9月26日 （星期五）下午二時四十分假座中華人民共和國上海市浦東新區平家橋路100弄6號7幢 15層舉行2025年第一次臨時股東大會（「臨時股東大會」），議程如下： 普通決議案(9) 特別決議案(9) – 1 – 1. 關於選舉獨立非執行董事的議案； 2. 關於修訂部分內部管理制度的議案； SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2025年9月5日 附註： – 2 – 7. 關於《公司2025年H股股票期權激勵計劃》的議案；及 8. 關於提請股東大會授權董事會及╱或計劃管理人辦理公司2025年H股股票 期權激勵計劃相關 ...